Heavy Metals: What is Actually in Your Body
Mercury, lead, arsenic, cadmium, aluminum, sources, mechanisms, diagnostics, and the logic of medical detoxification.
Specialty area at Vivecura: heavy-metal diagnostics & chelation therapy
Heavy-metal detoxification is one of my four focus areas, alongside Gut Reset, mold therapy, and ketamine-assisted treatment. I work with the DMPS provocation test according to the protocol of the German Medical Society for Metal Toxicology, and I run structured chelation cycles with full mineral monitoring.
Why I take this topic so seriously
Chronic exhaustion. Brain fog that no amount of sleep takes away. Muscle pain without an orthopedic finding. Mood swings without a psychiatric cause. Hormonal imbalances that respond to no therapy. And again and again the same sentence: “Your blood values are unremarkable.”
In such cases, when patients come who have already tried a lot, whose laboratory values seem fine, and whose suffering is real, I ask myself the next question: Which environmental toxins have never been measured?
Heavy metals sit right at the top of that list. Not because they are always the cause. But because they are systematically under-tested, and because the difference between a standard blood test and real tissue diagnostics is fundamental.
Over years in my practice I have seen a consistent finding: in patients who do not respond to classical and functional therapies, or only respond briefly, DMPS provocation tests show elevated mobilizable mercury in a notable number of cases, even when the spontaneous urine value was completely unremarkable. Under chelator influence, the body releases metals that it would not mobilize on its own. That is exactly the diagnostic value of this procedure.
Particularly striking: patients whose amalgam fillings were removed 10, 15, or 20 years ago, often without adequate protective measures, frequently still have relevant mobilizable amounts. That is not a coincidence. It is half-life mathematics. The mercury is not gone just because the filling is gone.
Mercury, the most familiar of the heavy metals
What mercury does in cells, the mechanism
Mercury binds with extreme affinity to thiol groups (-SH). These sit in cysteine residues of vital enzymes, in glutathione, and in selenocysteine residues of selenoproteins. The bond is nearly irreversible, and that is why mercury can affect so many different organ systems at once: wherever sulfur-containing enzymes sit at decisive switch points, mercury can interfere.
Blocked enzymes, what that means in everyday life
- Glutathione peroxidase: primary antioxidant enzyme → inhibition → oxidative stress, cell membrane damage, accelerated cellular aging
- Thioredoxin reductase: key selenoprotein enzyme. Hg binds selenocysteine with around 10⁶ times higher affinity than cysteine → functional selenium deficiency, even when blood selenium appears normal
- Mn-superoxide dismutase (Mn-SOD): mitochondrial antioxidant → blockade favors mitochondrial damage and chronic exhaustion at the cellular level
- Respiratory chain (complexes I, II, III): direct disturbance of energy production → ATP deficit → fatigue, cold intolerance, cognitive slowing
- Neuregulins and BDNF signaling: Hg disturbs synaptic plasticity and growth factors → brain fog, mood instability, cognitive losses
Why genetic susceptibility is so decisive
Not everyone responds equally to the same exposure. Polymorphisms in the genes CPOX4 (coproporphyrinogen oxidase), SLC6A4 (serotonin transporter), and MT1M/MT2A (metallothioneins) modulate individual susceptibility considerably. In the NIH-funded Casa Pia data, mercury exposure in boys with the SLC6A4 deletion allele explained up to 17.5% of the variance in a memory test, in wild type only 1.1%. At the population level no effect. In the genetically defined subgroup unmistakable.
That explains the apparent contradiction: the person at the next table with similar amalgam fillings has no symptoms, because they carry different metallothionein polymorphisms, are better supplied with selenium, or carry less systemic stress. That is biology, not imagination.
Methylmercury from fish, the underestimated everyday problem
Most of the people I test for heavy metals no longer have amalgam. And still we find mobilizable mercury. The most frequently overlooked cause: regular consumption of tuna, swordfish, or other large predatory fish.
Methylmercury is the organic form of mercury that becomes enriched in marine food chains by biomagnification. A tuna at the end of the food chain concentrates the mercury from thousands of smaller fish, up to one million times higher than the concentration in the surrounding water. The problem: methylmercury crosses the blood-brain barrier through a trick that inorganic mercury cannot use.
In the blood, methylmercury binds to the amino acid cysteine and forms a complex that structurally resembles the amino acid methionine. The L-type amino acid transporter (LAT1) at the blood-brain barrier, which normally transports methionine and leucine into the brain, recognizes this complex and actively shuttles it through. Inorganic mercury does not have this transport route, it has to diffuse passively, and does so far less efficiently. That makes methylmercury from fish neurobiologically more aggressive than the mercury vapor from amalgam.
Which fish is safe, and which is not?
The FDA has analyzed more than 1,300 commercial fish samples. The differences are dramatic, more than 100-fold between the safest and most dangerous species. The decisive variables: lifespan of the fish, position in the food chain, and geographic origin.
| Fish species | Avg Hg (ppm) | Burden | Recommendation |
|---|---|---|---|
| Swordfish | ⬛ Very high | Avoid | |
| Shark | ⬛ Very high | Avoid | |
| King mackerel | 🟧 High | Avoid | |
| Albacore tuna (canned) | 🟧 Mid-high | Limit (1×/week) | |
| Light tuna (canned) | 🟨 Medium | Limit (2×/week) | |
| Atlantic cod | 🟨 Low-medium | Moderate amounts | |
| Wild salmon (Atlantic/Pacific) | 🟩 Very low | Safe | |
| Sardines | 🟩 Very low | Safe | |
| Mackerel (Atlantic, small) | 🟩 Low | Safe |
Data: FDA Mercury in Commercial Fish 1990–2012 (n=1,300+ samples). EU limits: 0.3 mg/kg for most fish, 1.0 mg/kg for predators (tuna, shark, swordfish). Atlantic small mackerel does not equal king mackerel, a frequent confusion. ppm = mg/kg fresh weight.
The Faroe-Seychelles controversy, why the studies disagree
Two of the most important studies on prenatal methylmercury exposure reach opposite conclusions, and that is not a measurement error, it is biologically highly interesting.
1,022 children whose mothers regularly ate pilot whale (the main mercury source) were followed from birth. At school age: significant deficits in attention, memory, language, and fine motor skills. At 14: persistent impairments. At 22: cognitive deficits measurable even at maternal hair values of 10–20 µg/g, levels previously considered “safe.” This study formed the primary data basis for the US EPA reference value of 0.1 µg/kg/day.
Grandjean et al., Neurotoxicol Teratol. 1997; Budtz-Jørgensen et al., Neurotoxicol. 1999779 children of mothers who ate ocean fish (mean Hg in hair: 6.8 ppm), followed up to age 24, no consistent negative neurodevelopmental effects. The decisive difference from the Faroe study: a different mercury source, far more omega-3 fatty acids and selenium in the fish, hardly any PCB contamination (as is present in pilot whale). That suggests: mercury alone is not what decides, but the ratio of mercury to selenium, and the accompanying substances.
Myers et al., Neurotoxicol. 1997; Davidson et al., Neurotoxicol Teratol. 2017Mercury binds selenium with an affinity that is orders of magnitude higher than the cysteine bond. In fish with a positive Se:Hg ratio (more selenium moles than mercury moles), including salmon, sardines, cod, the selenium largely neutralizes the mercury. In fish with a negative ratio (swordfish, pilot whale), this protective buffer is missing. This approach (Selenium Health Benefit Value, HBVSe, Ralston & Raymond) explains why ocean-fish consumers do not necessarily take neurological harm despite measurable Hg blood levels, and why swordfish, despite Hg values similar to certain tuna, can be more dangerous.
Special risk: pregnancy and childhood
The developing nervous system is particularly vulnerable to methylmercury, because neuronal migration, synaptogenesis, and myelination are precisely timed processes that easily fall out of sync through ion channel disturbances and oxidative stress. FDA and EFSA recommend for pregnant women, breastfeeding mothers, and children up to age 12: no swordfish, shark, king mackerel, marlin, or bigeye tuna, and 2 to 3 portions (225 to 340 g) of low-mercury fish per week. This recommendation matters, because omega-3 fatty acids from fish are essential for brain development, the mistake would be to avoid all fish.
Lead, the forgotten omnipresence
The calcium-mimicry problem
Lead is so dangerous toxicologically because it biochemically imitates calcium. The Pb²⁺ ion has a similar ionic radius to Ca²⁺ and carries the same charge. With this, calcium channels open, lead enters cells, activates calcium-dependent signaling pathways in faulty ways, and displaces calcium from bone, neurons, and heart muscle cells.
What lead does in the body, system overview
- Nervous system (children): for every 1 µg/dL increase in blood level, measurable IQ reduction. No lower threshold known. The CDC has stepwise lowered the reference value since 1971 from 60 to 3.5 µg/dL (2021), and states: there is no safe blood level for children.
- Cardiovascular system: lead reduces nitric oxide bioavailability, raises angiotensin II, and promotes atherosclerosis. Menke et al. (2006, Circulation, n=13,946): hazard ratio 1.55 for cardiovascular mortality at blood Pb ≥ 3.62 µg/dL versus < 1.94 µg/dL. Lanphear et al. (2018): around 412,000 annual US deaths from lead-related cardiovascular disease.
- Inhibition of hemoglobin synthesis: lead blocks δ-aminolevulinic acid dehydratase (ALAD) and accumulates neurotoxic ALA precursors, one of the oldest known toxicological effects.
- Bone as a silent depot: a 20 to 30 year half-life means: the lead from a childhood exposure in a 1970s pre-war building is in a 50-year-old today still around 50% present. With menopause, fractures, or illnesses with bone loss, this lead is remobilized.
- Epigenetic changes: prenatal lead exposure demonstrably alters DNA methylation patterns in key genes of the immune and nervous systems, effects that have been observed across generations.
The TACT trial (2003–2012, n=1,708 patients after myocardial infarction) showed an 18% reduction in cardiovascular events (HR 0.82, p=0.035) through EDTA chelation. In diabetics the effect was dramatic: HR 0.59 (NNT 6.5). The follow-up trial TACT2 (2024) was negative, presumably because baseline lead levels in the current population have significantly fallen. The TACT data suggest: in people with significant lead body burden, EDTA chelation may reduce cardiovascular risk.
Lamas GA et al. JAMA. 2013;309(12):1241–1250 (TACT) · Lamas GA et al. ACC 2024 (TACT2, preliminary negative)Arsenic, the poison in rice and drinking water
The methylation paradox, why genetics decides
Arsenic is converted in the body via the AS3MT enzyme through a methylation cascade: inorganic arsenic → MMA(III) → DMA(V). The problem: the intermediate MMA(III) (monomethylarsonous acid, trivalent) is more toxic than the original inorganic arsenic, not less. Anyone who eats arsenic-rich food and methylates poorly accumulates this particularly damaging intermediate.
AS3MT activity varies extremely between population groups. Indigenous Andean communities, who have been consuming arsenic-rich drinking water for generations, carry protective AS3MT polymorphisms in 72 to 76% frequency, possibly the result of evolutionary selection. These variants produce more DMA(V) and less MMA(III), which is associated with lower cancer risk. Folate and vitamin B12 are direct regulators of this methylation pathway, an argument for methylation support as a protective strategy.
Cadmium, the silent kidney killer
Kidney toxicity and the Itai-itai disease
The organ target of cadmium is the proximal renal tubule. Cadmium-metallothionein complexes are filtered glomerularly and tubularly reabsorbed, where they accumulate up to a critical cortex concentration of about 200 µg/g. The first measurable biomarker is elevated beta-2 microglobulin in urine (> 300 µg/g creatinine). Advanced cadmium damage leads to Fanconi syndrome: renal calcium and phosphorus loss, osteomalacia, and osteoporosis.
The most familiar historical example: the Itai-itai disease in Japan (1950s to 1970s) in the Jinzu river basin, where industrial cadmium contaminated the groundwater. Affected (predominantly post-menopausal women with malnutrition) developed extreme bone pain and multiple spontaneous fractures. 196 officially recognized cases, many more undiagnosed.
Cadmium binds and directly activates the estrogen receptor alpha (ERα) with an affinity comparable with 17β-estradiol, it is a metalloestrogen. In laboratory models, cadmium stimulates estrogen-responsive gene expression, breast cancer cell proliferation, and PCOS-like ovarian changes. In epidemiological studies, blood cadmium correlates with increased breast cancer risk in postmenopausal women. This has clinical relevance: in patients with unexplained estrogen dominance, cycle disturbances, or hormonally associated cancer risk, cadmium should not be missing from the toxin history.
DMPS and DMSA do not have established efficacy in chronic cadmium burden, and they may even raise renal burden if cadmium is mobilized in larger amounts without being optimally excreted. In acute cadmium poisoning (a rare exception), DMSA can be used immediately after exposure. For chronic exposure: smoking cessation is the most effective intervention. Supportive: zinc and calcium competitively inhibit Cd uptake in the gut; an optimized nutrient status reduces biological availability.
Aluminum, the most controversial metal
What is proven, and what is not
The dialysis encephalopathy of the 1970s and 1980s proves: aluminum is a potent neurotoxin at high concentrations. Patients who received aluminum-containing dialysis fluids and phosphate binders developed speech and movement disorders, seizures, and dementia. This finding is undisputed. But the neuropathology does not resemble Alzheimer’s disease, no amyloid plaques, no tau filaments, no neurodegenerative progression pattern.
Rondeau et al. (PAQUID cohort, 2000): Al > 0.1 mg/L in drinking water → relative Alzheimer’s risk 2.20 (95% CI: 1.24–3.89). Silicon ≥ 11.25 mg/L was protective (RR 0.75). Further studies have not consistently replicated this finding. Meta-analyses tend to show elevated aluminum levels in brain, serum, and CSF of Alzheimer’s patients, but causality remains unproven. EFSA and Alzheimer’s societies classify the evidence as inconsistent.
Rondeau V et al. Am J Epidemiol. 2000;152(1):59–66 · Lidsky TI. J Occup Environ Med. 2014;56(Suppl 5)Silicon-rich mineral water as natural elimination
Orthosilicic acid in silicon-rich mineral water (≥ 30 mg/L) forms with aluminum soluble hydroxyaluminosilicate complexes, which are renally excreted. Davenward et al. (2013) gave 15 Alzheimer’s patients up to 1 liter daily over 12 weeks, aluminum body burden fell measurably, and 3 of 15 patients showed clinically relevant cognitive improvement. The evidence is preliminary and methodologically limited (small open study, no control group). But the intervention is safe, low-threshold, and inexpensive, which makes it sensible as part of a more comprehensive protocol.
The cocktail effect, why single limits lie
All limits, for mercury in fish, lead in drinking water, cadmium in food, are set in isolation. That is regulatorily pragmatic, but biologically potentially dangerous. When multiple heavy metals are present at the same time, their toxicities do not simply add up, they multiply.
Schubert et al. (1978, Journal of Toxicology and Environmental Health) combined sublethal doses of mercury and lead in rats: although both doses alone caused no or barely any deaths, 100% of the animals died with the combination. This finding is 46 years old and is still not fully accounted for in regulatory practice.
Newer data confirm the mechanism: Frontiers in Public Health (2023) showed that Pb/Hg/Cd mixtures in mice produce significantly stronger neurobehavioral impairments than any single metal alone, via disruption of dopaminergic and serotonergic systems in the striatum. The ATSDR (US Agency for Toxic Substances) holds: arsenic-cadmium-lead combinations show greater-than-additive effects on neurological endpoints.
Patients who had amalgam, regularly eat tuna, lived in a pre-war building with lead pipes, and smoke, or used to smoke, carry a cumulative metal mixture burden that may, in its totality, be toxicologically more relevant than any single measurement suggests. That is an argument for the overall view and against thinking in single limits.
Typical symptom patterns, what I see in practice
Heavy-metal burdens show no pathognomonic symptoms, that is one of the central diagnostic problems. The complaints overlap with burnout, thyroid disease, autoimmune processes, mold burden, and chronic stress. What I do: I look at the pattern, not at a single symptom.
Energy & nervous system
- Chronic exhaustion, no restorative sleep
- Performance drops after small loads
- Brain fog, concentration problems
- Inner restlessness, irritability
- Sleep problems, trouble falling asleep
- Cold intolerance without thyroid finding
Muscles & joints
- Diffuse muscle pain without finding
- Wandering joint and tendon pain
- Morning stiffness, cramps
- Slow recovery after exercise
- Muscle tremor, coordination problems
- Carpal-tunnel-like complaints
Gut & detoxification
- Bloating, alternating stools
- New food intolerances
- Paradoxical reactions to antioxidants
- Liver values elevated without clear cause
- Metallic taste in the mouth
- Heightened chemical sensitivity
Psyche, hormones & circulation
- Depressive symptoms without psychiatric cause
- Heart palpitations (cardiology unremarkable)
- Blood pressure swings, dizziness
- Hormonal imbalances without endocrine finding
- Borderline elevated kidney values
- “Not feeling quite like yourself anymore”
Why the blood test so often lies
“But my mercury blood value was normal.” I hear this sentence regularly. And it is mostly correct, and at the same time largely meaningless for the question of tissue burden.
Blood is primarily a transport medium, not a storage organ. It shows what is currently circulating, not what is bound in tissue. And of the relevant heavy metals, a large share is stored in tissue:
Half-lives and storage sites at a glance
Bar width = relative residence time. Blood measurement primarily shows the short-term transport fraction, not the cumulative tissue burden, which is toxicologically decisive.
The half-life math, why 10 infusions do more than 10 years of waiting
Imagine that at age 30 you had your last amalgam fillings removed. The fillings are gone, but the mercury that has accumulated over years in brain tissue is still there.
If the half-life of inorganic mercury in the brain is around 15 to 27 years, that means: Without active intervention, you would be 45 to 57 years old before half is naturally excreted. Until three quarters are gone: another 30 to 54 years.
With a single DMPS infusion, the body excretes more mercury renally in a few hours than it would in many weeks without intervention. Cumulatively, over 8 to 12 cycles, a portion of the mobilizable tissue burden is actively reduced, the kind that the body alone would only shed over decades. That is not magic. That is pharmacology.
27Diagnostics, what I actually measure
There is no single perfect diagnostic test for heavy metals. Every test has a particular informative value, a particular limitation, and a particular clinical context in which it is sensible. That is not a weakness, that is toxicology.
Baseline lab work, what I always order
Complete blood count, kidney function (creatinine, cystatin C, GFR), liver values (AST, ALT, GGT), thyroid (TSH, possibly fT3/fT4), ferritin/iron, zinc, selenium, magnesium, vitamin D. This baseline status is mandatory before any further metal diagnostics, because it estimates the system’s detoxification capacity and prevents other causes from being missed.
Spontaneous urine (screening), first orientation
Several-hour or morning urine sample for mercury, lead, cadmium, arsenic, possibly aluminum. The German HBM-I values (Federal Environment Agency): Hg 5 µg/L blood, 7 µg/L urine. These values give a first orientation, but a normal finding does not exclude significant tissue burden. Particularly important: arsenic speciation (separate measurement of iAs, MMA, DMA) and time interval to the last fish consumption (at least 72 hours for valid Hg measurement).
DMPS provocation test, the heart of heavy-metal diagnostics
Intravenous DMPS administration (individually dosed by body weight and kidney function), followed by a 4 to 6 hour urine collection and measurement of mobilized metals in a specialized laboratory. This test shows what the body releases under chelator influence from the tissue-blood equilibrium, that is, the mobilizable burden, not just what circulates. Performed according to the protocol of the German Medical Society for Metal Toxicology (AGM). Important: the test is diagnostic, not therapeutic. The provocation infusion does excrete metals, but a structured therapy cycle is something distinct. Note: American toxicology societies (ACMT) reject the post-chelator provocation test as a diagnostic instrument, since population-based reference ranges do not exist. In German integrative medicine it is still used. I use it as one building block in clinical context, not as a stand-alone proof.
Porphyrin profile in urine, functional biomarker
Mercury specifically inhibits the enzyme uroporphyrinogen decarboxylase, which leads to accumulation of precoproporphyrin in the urine, a pattern considered highly specific for Hg burden. This test does not measure metal concentration but the biological effect of the metal on the enzyme system. Particularly valuable in patients whose provocation test is borderline but whose clinical picture strongly points to metal burden.
MELISA test, immunological reactivity
The Memory Lymphocyte Immunostimulation Assay measures T-cell sensitization to various metals and dental materials. Important: MELISA measures immunological sensitivity, not toxic body burden. Those are different questions. A patient may have a high body burden without MELISA reactivity, and vice versa. I use MELISA when autoimmune processes are at the foreground or when the decision about amalgam removal is approaching and the compatibility of alternative materials needs to be checked.
Hair mineral analysis, limited but specific use
Hair reflects systemic metal exposure 1 to 3 months back. The main limitation: external contamination through shampoos, hair dyes, and environment. EPA and CDC do not recommend hair analysis for clinical decisions. One relevant exception: chronic arsenic exposure, because arsenobetaine from seafood (which distorts urine tests) does not accumulate in hair. In selected constellations, hair can be sensible. As a stand-alone diagnostic test it is too unreliable.
DMPS: how chelation therapy works physiologically
DMPS (2,3-dimercapto-1-propanesulfonic acid) is not a miracle drug. It is a precisely acting molecule with a clearly describable mechanism. Once you understand what DMPS does physiologically, and what the body would do without it, the logic becomes evident.
Distribution in the extracellular space
DMPS is administered intravenously and quickly distributes into blood and the extracellular space. It barely penetrates the blood-brain barrier, a safety advantage, because deep CNS deposits are not abruptly mobilized. It acts where mercury currently circulates: in blood, extracellular fluid, on membrane surfaces.
The pincer-grip principle of chelation
DMPS has two free -SH groups. These clamp onto the Hg²⁺ ion at two points simultaneously, the resulting ring bond is more stable than any monodentate sulfur group. DMPS competes successfully against the body’s own glutathione, cysteine residues, and other thiol biomolecules for the mercury, and wins. The result: a water-soluble, biochemically inert DMPS-Hg complex.
Mobilization out of the tissue-blood equilibrium
Mercury in tissue stands in dynamic equilibrium with blood, a small share constantly circulates. When DMPS binds and removes free Hg in the blood, this equilibrium shifts: more Hg moves out of tissue storage into the bloodstream and is bound at once, before it can re-deposit. This gradient effect is the actual therapeutic core, active interception, not passive waiting.
Renal excretion in hours instead of decades
The DMPS-Hg complex is water-soluble and renally excreted. It is actively tubularly secreted and excreted in high concentrations in urine within 4 to 6 hours. In a single infusion night, the body excretes more mercury than it would in months without intervention. Cumulatively, over a complete cycle: a measurable reduction of the mobilizable burden.
Cycles instead of a single dose
A single cycle does not mobilize everything. Tissue releases Hg stepwise, that is why we work in cycles with controlled pauses, during which minerals are rebuilt and the system recovers. The amounts excreted per infusion typically decrease over the course, a sign that the mobilizable burden is dropping.
“The body excretes mercury, but at the efficiency of an hourglass. Chelation therapy is the step that turns the hourglass 90 degrees.”
Shukri Jarmoukli, Vivecura BerlinChelators in comparison, pharmacological and natural
There is a fundamental pharmacological difference between systemic chelators and so-called “natural detox agents,” and I communicate this difference honestly because it is central to the therapeutic decision.
Zeolite, activated charcoal, chlorella, and pectin work in the gut: they interrupt the enterohepatic circulation and capture metals that are excreted via bile. That is a sensible building block, but they do not enter blood, the extracellular space, or tissue. They do not shift any tissue-blood equilibrium. The pharmacological difference from systemic chelators is fundamental, not gradual. In my practice I use binders as adjunctive measures, never as a replacement for systemic chelation in relevant tissue burden.
What concretely awaits you at Vivecura
No one-size-fits-all schema. But clear principles I apply with every patient, individually adapted, in a sequence that protects the system rather than overwhelming it.
History & system status
- Detailed exposure and symptom history
- Dental and amalgam history, fish-consumption pattern
- Living and occupational history (pre-war buildings, industry)
- Previous therapy attempts and reactions
- Bioimpedance analysis (BIA): cell status
- HRV measurement: autonomic nervous system status
Diagnostics
- Baseline lab: kidney, liver, minerals, thyroid
- Spontaneous urine with metal panel (screening)
- DMPS provocation test according to AGM protocol
- Where indicated, porphyrin profile (functional Hg marker)
- Where indicated, MELISA when autoimmune is suspected or for amalgam removal planning
- Selenium, zinc, glutathione (antioxidant capacity)
Preparation & chelation cycles
- Build up minerals and glutathione (4 to 6 weeks)
- Stabilize gut and liver, elimination has to work
- DMPS infusions, individually dosed, 8 to 12 cycles
- Mineral monitoring after each infusion
- Cyclic pauses for regeneration and substitution
- Tracking of excretion amounts over the course
Course & regeneration
- Repeat provocation: how has the burden changed?
- IV nutrient infusions: vitamin C, glutathione, B complex
- Phosphatidylcholine in neurotoxic burden
- Nutrition and lifestyle optimization
- Video consultations possible for follow-up and adjustment
- Honest discussion: another cycle or close out?
Over years I have made a consistent finding: even in patients whose spontaneous urine and blood mercury values were completely unremarkable, post-DMPS urine samples in a notable number of cases show elevated mercury excretion. Under chelator influence, the body releases mercury that it would not mobilize on its own.
One particularly clear case: Markus, 47, Berlin. Persistent exhaustion after a COVID infection, elevated liver enzymes (ALT 62 U/L), brain fog for 7 months. Spontaneous Hg unremarkable. Amalgam removed 18 years earlier. Chelator provocation test: clearly elevated mercury excretion. After 8 cycles over 6 months with accompanying mineral monitoring: ALT normalized (34 U/L), subjective cognitive improvement, sleep quality clearly better.
I communicate this transparently: this is a clinical observation, not a randomized trial. Causality cannot be proven here. But the pattern, Hg burden despite old amalgam removal, measurable excretion under chelator, clinical improvement over the course, is consistent enough in my practice to take this building block seriously.
Heavy metals within the system, the connection to my other specialty areas
Heavy-metal burdens rarely come alone. They interact with the gut (impaired elimination), with mold toxins (blocked detoxification enzymes), and with the nervous system (neuroinflammation that limits psychiatric treatments). My four specialty areas are no coincidence, they are a system.
Heavy metals
Long-term storage, tissue burden, chelation therapy
this areaGut Reset
Metal elimination via bile and stool, without a healthy gut no efficient detox loop
Mold
Mycotoxins block glutathione synthesis and metallothioneins, with simultaneous mold burden, heavy-metal detoxification worsens
Ketamine
Neurotoxic heavy-metal burden can limit the success of psychiatric treatments, lower toxin load, then open the healing window
Evidence overview, what we know and what we do not
| Statement | Evidence level | Limitation |
|---|---|---|
| Amalgam releases Hg vapor | Strongly documented | Causal harm in healthy adults at the group level not proven |
| MeHg from fish damages the prenatal nervous system | Human studies (Faroe) | Seychelles study disagrees, selenium protection as a possible explanation |
| Genetic vulnerability (CPOX4, MT, SLC6A4) | RCT data (NIH) | Holds for genetically defined subgroups, not all |
| Hg half-life in brain: many years | Toxicokinetic models | Direct in-vivo measurement in humans difficult; estimates 15–27 years |
| Lead: no safe limit | CDC, human studies | IQ effects detectable already below 5 µg/dL; consensus view |
| Lead and cardiac risk (TACT) | 1 positive RCT, 1 negative | TACT2 negative, presumably due to lower baseline lead levels |
| Arsenic: IARC group 1 carcinogen | Established (human) | Skin, lung, bladder, especially in high drinking-water exposure |
| Cd: kidney damage / hormonal action | Human / in-vitro mechanism | Kidney: human studies solid. Estrogenic action: in-vitro well documented, human limited |
| Al: Alzheimer’s link | Epidemiology inconsistent | Dialysis encephalopathy proves neurotoxicity, direct Alzheimer’s causality unproven |
| DMPS mobilizes Hg renally | Pharmacologically documented | Extent of tissue mobilization individually variable |
| Chelation therapy in chronic amalgam exposure | Clinical experience | Grandjean 1997 RCT (n=50) showed no superiority in mild exposure; larger RCTs missing |
| Cocktail effect (Hg + Pb synergy) | Animal experiment (Schubert 1978) | Human dose extrapolation still incomplete; barely accounted for in regulation |
A story from my family that brings it all to the point
My aunt is a dentist. For more than 15 years she has suffered from Hashimoto thyroiditis, severe hormonal complaints, weight gain despite diets, massive food intolerances, and chronic exhaustion. She has truly tried everything. Dietary changes, hormone therapies, elimination diets, supplement protocols. Short-term improvements, but never a real turn. Her body seemed to sabotage whatever she tried.
For years I have voiced the suspicion that heavy metals could play a role. As a dentist, she had decades of daily contact with amalgam. Drilling, removing, placing. Even with protective measures, the exposure is considerable. Mercury vapor is invisible. And it accumulates.
Her husband is the chief physician of a hematology and oncology clinic in the United States. He is brilliant, experienced, and deeply rooted in classical medicine. For five years he kindly smiled at my suspicion. Heavy metals, functional medicine, DMPS testing. He listened, nodded politely, and let it go.
Then my aunt decided to do the DMPS provocation test. The results were unambiguous: extraordinarily high mobilizable mercury amounts. A burden that had built up over decades of professional exposure and that no standard blood test had ever shown.
She began chelation therapy. What happened next surprised everyone, perhaps her most of all. The weight that had not yielded to any diet for 15 years began to drop. The energy came back. The intolerances became fewer. She feels more alive than she has in years.
Her husband, the oncologist, no longer laughed at me. He had himself examined and treated functional-medically. He is slowly letting go of the idea that conventional diagnostics captures all relevant burdens. First the proof, then the change. That is human. And I understand it.
What I take from this story: not every cause is recognized with the tools you are used to. Sometimes a different question is needed to find a new answer.
Could this be relevant for you? Help with self-assessment.
What follows is not a diagnosis and not a substitute for a medical history. It is an honest invitation to pause and reflect. Heavy metals show no pathognomonic symptoms. They rarely appear as a clear cause. But they can act as silent co-contributors for years in the background, without anyone ever asking about them.
I think the following people should seriously consider whether heavy-metal diagnostics would make sense for them. Not as fear-mongering. As an informed decision.
Group 1: exposure that many have forgotten
- Amalgam fillings, now or earlier: you had amalgam fillings, perhaps removed 10, 15, or 20 years ago. The mercury is not gone just because the filling is gone. The half-life in the brain reaches up to 27 years.
- Occupational amalgam exposure: you are or were a dentist, dental technician, or dental assistant. Years of contact with amalgam during placement and removal means an exposure that goes far beyond normal, even with protective measures.
- Regular consumption of tuna or swordfish: anyone who eats tuna two to three times per week can build up a relevant methylmercury burden over months and years without noticing.
- Pre-war building, lead pipes, or lead-based paint: you live in a building constructed before 1970. You know your water pipes are made of lead, or you suspect it. Berlin pre-war buildings are particularly relevant here.
- Smoking, now or earlier: cadmium accumulates in the kidney with a half-life of 10 to 30 years. Anyone who has smoked carries this burden for a long time without knowing.
- Regular rice consumption, especially rice milk or rice cakes: arsenic accumulates preferentially in rice plants. Anyone who eats rice as a main grain should have their arsenic status checked once.
Group 2: symptoms without a satisfying explanation
- Brain fog that does not go away: you feel mentally as if behind glass. Concentration problems, word-finding difficulties, a head that feels foggy. And all blood tests were normal.
- Chronic exhaustion without a clear cause: you sleep eight hours and are still not rested in the morning. Small loads exhaust you disproportionately. Thyroid, blood count, all unremarkable.
- Hormonal imbalances that respond to no therapy lastingly: cycle disturbances, PMS, unexplained weight gain, estrogen dominance without a clear endocrine cause. Cadmium and zearalenone act as metalloestrogens and can directly disturb the hormone system.
- Thyroid disease, especially Hashimoto: mercury directly attacks selenoenzymes that are needed for thyroid hormone activation. There is no proven causality. But the mechanistic plausibility is large enough that I always ask about heavy-metal history in Hashimoto.
- Autoimmune disease of any kind: rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease. Heavy metals can act as chronic triggers for immune activation. No physician can guarantee they play a role. But no physician can guarantee that they do not, either, without having measured.
- Wandering muscle and joint pain without an orthopedic finding: diffuse pain that does not really fit anywhere. MRI unremarkable. Rheumatoid factor negative. No inflammatory finding. And still this pain.
- Mental health problems that do not respond stably to any classical therapy: depression, anxiety disorders, emotional instability, a nervous system that seems permanently on alarm. When neurobiological toxicity destabilizes the foundation, psychotherapeutic and medication treatments can only reach so far.
- Kidney values that stay borderline for years: slightly elevated creatinine, slowly falling GFR without a clear cause. Cadmium attacks the proximal renal tubules preferentially, for years without symptoms.
- Intolerances that keep accumulating: food intolerances that slowly expand. A body that reacts to ever more things. Heavy metals can destabilize the gut barrier and chronically activate the immune system, which prepares the ground for intolerances.
- Therapy resistance as a pattern: you have tried a lot. You have had many diagnoses. Many things briefly helped, but nothing took hold lastingly. For me this is one of the strongest clinical signals. Not because heavy metals are always the cause, but because as a silent background load they can sabotage other therapies.
I consider it medically defensible and sensible to initiate structured heavy-metal diagnostics in any person who suffers from one or more chronic conditions, who has demonstrably been exposed to relevant sources, or who, despite solid therapy attempts, has not achieved stable improvement. Not as the only answer. As one building block in a more complete picture. The question is not: “Is this heavy metals?” The question is: “Have we ever sufficiently checked this?”
These questions do not replace a medical history or laboratory diagnostics. They are an orientation aid, not a diagnosis. Not everyone with exhaustion has a heavy-metal burden. And a heavy-metal burden does not automatically explain all symptoms. What matters is the overall clinical context. That is what the first appointment is for.
Scientific sources
- DeRouen TA et al. Neurobehavioral effects of dental amalgam in children (Casa Pia Trial). JAMA. 2006;295(14):1644–1652.
- Bellinger DC et al. Neuropsychological and renal effects of dental amalgam in children. JAMA. 2006;295(14):1623–1632.
- Woods JS et al. Genetic polymorphisms affecting susceptibility to mercury neurotoxicity (Casa Pia substudy). Neurotoxicology. 2014;44:242–249.
- Ajsuvakova OP et al. Sulfhydryl groups as targets of mercury toxicity. Coord Chem Rev. 2020;417:213343.
- Grandjean P et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury (Faroe). Neurotoxicol Teratol. 1997;19(6):417–428.
- Myers GJ et al. Seychelles Child Development Study (Outcome 66 months). Neurotoxicol Teratol. 1997;19(6):401–416.
- Davidson PW et al. Neurodevelopmental outcomes in Seychelles at age 22 and 24. Neurotoxicol Teratol. 2017;62:69–76.
- Ralston NVC, Raymond LJ. Mercury’s neurotoxicity is characterised by its disruption of selenium biochemistry. Biochim Biophys Acta. 2018;1862(11):2405–2416.
- FDA. Mercury Levels in Commercial Fish and Shellfish 1990–2012. fda.gov.
- EU Regulation 2023/915 on maximum levels for contaminants in food.
- Rooney JPK. The retention time of inorganic mercury in the brain, systematic review. Toxicol Appl Pharmacol. 2014;274(3):425–435.
- Charkiewicz AE et al. Mercury exposure and health effects. Int J Mol Sci. 2025;26(5):2326.
- Menke A et al. Blood lead below 0.48 µmol/L and mortality among US adults. Circulation. 2006;114(13):1388–1394.
- Lanphear BP et al. Low-level lead exposure and mortality in US adults. Lancet Public Health. 2018;3(4):e177–e184.
- Needleman HL et al. IQ and blood lead levels, pooled international analysis. Environ Health Perspect. 2005;113(7):894–899.
- Lamas GA et al. Effect of disodium EDTA chelation regimen on cardiovascular events (TACT). JAMA. 2013;309(12):1241–1250.
- Lamas GA et al. TACT2, EDTA Chelation in Diabetic Post-MI Patients (negative). ACC. 2024.
- IARC Monographs. Arsenic and arsenic compounds. IARC Monogr Eval Carcinog Risks Hum. 2012;100C.
- Vahter M. Mechanisms of arsenic biotransformation (AS3MT). Toxicology. 2002;181–182:211–217.
- EFSA. Arsenic in food, Scientific Opinion. EFSA Journal. 2009;7(10):1351.
- Stoica A et al. Cadmium activates estrogen receptor alpha. Cancer Res. 2000;60(20):5844–5849.
- Järup L, Akesson A. Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol. 2009;238(3):201–208.
- EFSA. Cadmium dietary exposure in the European population. EFSA Journal. 2012;10(1):2551.
- Rondeau V et al. Aluminum and silica in drinking water and the risk of Alzheimer’s disease. Am J Epidemiol. 2000;152(1):59–66.
- Lidsky TI. Is the aluminum hypothesis dead? J Occup Environ Med. 2014;56(Suppl 5):S73–S79.
- Davenward S et al. Silicon-rich mineral water as a non-invasive test of the aluminum hypothesis in Alzheimer’s disease. J Alzheimers Dis. 2013;33(2):423–430.
- Schubert J et al. Combined effects in toxicology, cadmium, mercury, and lead. J Toxicol Environ Health. 1978;4(5–6):763–776.
- Grandjean P et al. Chelating treatment in patients with symptoms attributed to amalgam fillings, RCT. Occup Environ Med. 1997;54(3):180–188.
- DMPS (Dimaval®) prescribing information. Heyl Chem.-pharm. Fabrik GmbH, Berlin. BfArM approval since 1996.
- Aposhian HV et al. Vitamin C, glutathione, lipoic acid did not decrease brain/kidney mercury in rats. J Toxicol Clin Toxicol. 2003;41(4):491–500.
- EU Council. Council Directive 2020/2184 on drinking water quality (Pb limit 5 µg/L). 2020.
- Pamphlett R, Bishop DP. Mercury in neurons in Parkinson’s disease regions. PLoS One. 2022;17(1):e0262464.
- Cheng H et al. Heavy Metals Toxicity: Mechanism, Health Effects, and Therapeutic Interventions. MedComm. 2025. DOI: 10.1002/mco2.70241.